Increased phosphorylation on residue S795 of the retinoblastoma protein in esophageal adenocarcinoma.

作者: AKUENI L. DAVELAAR , DANIELLE STRAUB , KAUSHAL B. PARIKH , LIANA LAU , PAUL FOCKENS

DOI: 10.3892/IJO.2015.3040

关键词:

摘要: Due to its increasing incidence and relatively poor prognosis, esophageal adenocarcinoma (EAC) is becoming a significant health problem. Elucidating the mechanisms underlying EAC development of great importance improve upon current conventional treatment strategies. Insight into phosphorylation has proven be useful for diagnostic molecular strategies in cancer. A pathway largely dependent on frequently deregulated cancer cell cycle regulating p16-retinoblastoma (Rb) pathway. We investigated kinase activity, specifically within p16-Rb pathway, EAC. high-throughput peptide tyrosine array containing short peptides representing 100 proteins with known sites, was used assess activity Also, specific changes protein Rb upstream regulator P16 were validated through immunoblotting normal cells tissues. Phosphorylation higher tissues as compared squamous majority significantly phosphorylated found involved structure maintenance immunity. Validation biopsy specimens lines showed hyper associated aberrant expression The (S795) residue tissue (Wilcoxon paired rank test, p=0.004). Investigation may indicate targets intervention give more insight

参考文章(40)
M. Kitagawa, H. Higashi, H. K. Jung, I. Suzuki-Takahashi, M. Ikeda, K. Tamai, J. Kato, K. Segawa, E. Yoshida, S. Nishimura, Y. Taya, The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. The EMBO Journal. ,vol. 15, pp. 7060- 7069 ,(1996) , 10.1002/J.1460-2075.1996.TB01097.X
Mark J Cossentino, Roy K H Wong, Barrett's esophagus and risk of esophageal adenocarcinoma. Seminars in gastrointestinal disease. ,vol. 14, pp. 128- 135 ,(2003)
Y. Gu, J. Rosenblatt, D.O. Morgan, Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. The EMBO Journal. ,vol. 11, pp. 3995- 4005 ,(1992) , 10.1002/J.1460-2075.1992.TB05493.X
Jesper Lagergren, Pernilla Lagergren, Recent developments in esophageal adenocarcinoma CA: A Cancer Journal for Clinicians. ,vol. 63, pp. 232- 248 ,(2013) , 10.3322/CAAC.21185
J. H. Rubenstein, J. B. Taylor, Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Alimentary Pharmacology & Therapeutics. ,vol. 32, pp. 1222- 1227 ,(2010) , 10.1111/J.1365-2036.2010.04471.X
Chin Hur, Melecia Miller, Chung Yin Kong, Emily C. Dowling, Kevin J. Nattinger, Michelle Dunn, Eric J. Feuer, Trends in esophageal adenocarcinoma incidence and mortality Cancer. ,vol. 119, pp. 1149- 1158 ,(2013) , 10.1002/CNCR.27834
Kjell M. Kaune, Christine Neumann, Christian Hallermann, Florian Haller, Michael P. Schön, Peter Middel, Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas. Experimental Dermatology. ,vol. 20, pp. 331- 335 ,(2011) , 10.1111/J.1600-0625.2010.01226.X
Mohamed MM Abdel-Latif, Shane Duggan, John V Reynolds, Dermot Kelleher, Inflammation and esophageal carcinogenesis. Current Opinion in Pharmacology. ,vol. 9, pp. 396- 404 ,(2009) , 10.1016/J.COPH.2009.06.010
A. Poehlmann, D. Kuester, P. Malfertheiner, T. Guenther, A. Roessner, Inflammation and Barrett's carcinogenesis. Pathology Research and Practice. ,vol. 208, pp. 269- 280 ,(2012) , 10.1016/J.PRP.2012.03.007
Alvarez Hector, Elizabeth A Montgomery, Collins Karikari, Marcia I Canto, Kerry B Dunbar, Jean S Wang, Georg Feldmann, Seung-Mo Hong, Michael C Haffner, Alan K Meeker, Sacha J Holland, Jiaxin Yu, Thilo J Heckrodt, Jing Zhang, Pingyu Ding, Dane Goff, Rajinder Singh, Juan Carlos Roa, Arivusudar Marimuthu, Gregory J Riggins, James R Eshleman, Barry D Nelkin, Akhilesh Pandey, Anirban Maitra, None, The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma Cancer Biology & Therapy. ,vol. 10, pp. 1009- 1018 ,(2010) , 10.4161/CBT.10.10.13248